Stuart MD - ArriVent BioPharma, President CoFounder
| AVBP Stock | 27.45 0.86 3.23% |
President
Stuart MD is President CoFounder of ArriVent BioPharma, Common
| Age | 64 |
| Address | 18 Campus Boulevard, Newtown Square, PA, United States, 19073 |
| Phone | 628-277-4836 |
| Web | https://www.arrivent.com |
ArriVent BioPharma, Management Efficiency
The company has return on total asset (ROA) of (0.2122) % which means that it has lost $0.2122 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3103) %, meaning that it created substantial loss on money invested by shareholders. ArriVent BioPharma,'s management efficiency ratios could be used to measure how well ArriVent BioPharma, manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/25/2024, Return On Tangible Assets is likely to drop to -0.45. In addition to that, Return On Capital Employed is likely to drop to -0.52. As of 11/25/2024, Non Current Liabilities Total is likely to grow to about 213.7 K, while Total Current Liabilities is likely to drop slightly above 8 M.Similar Executives
| Found 5 records | PRESIDENT Age | ||
| Benjamin Bressler | Lindblad Expeditions Holdings | 61 | |
| Jennifer Koester | Sphere Entertainment Co | N/A | |
| David GranvilleSmith | Sphere Entertainment Co | 57 | |
| Tyler Skarda | Lindblad Expeditions Holdings | 59 | |
| Andrea Greenberg | Sphere Entertainment Co | 65 | |
Management Performance
| Return On Equity | -0.31 | ||||
| Return On Asset | -0.21 |
ArriVent BioPharma, Leadership Team
Elected by the shareholders, the ArriVent BioPharma,'s board of directors comprises two types of representatives: ArriVent BioPharma, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ArriVent. The board's role is to monitor ArriVent BioPharma,'s management team and ensure that shareholders' interests are well served. ArriVent BioPharma,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ArriVent BioPharma,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Meghna Chowdary, Senior Strategy | ||
| James JD, General Secretary | ||
| Dandan Dong, Chief Officer | ||
| Robin MA, CoFounder COO | ||
| Winston MBA, CFO Treasurer | ||
| Zhengbin Yao, Chairman, CoFounder | ||
| Stuart MD, President CoFounder | ||
| Yang Wang, Chief Officer |
ArriVent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ArriVent BioPharma, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.31 | ||||
| Return On Asset | -0.21 | ||||
| Current Valuation | 499.58 M | ||||
| Shares Outstanding | 33.59 M | ||||
| Shares Owned By Insiders | 13.64 % | ||||
| Shares Owned By Institutions | 64.80 % | ||||
| Number Of Shares Shorted | 3.54 M | ||||
| Price To Book | 2.69 X | ||||
| EBITDA | (74.59 M) | ||||
| Net Income | (69.33 M) |
Pair Trading with ArriVent BioPharma,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ArriVent BioPharma, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ArriVent BioPharma, will appreciate offsetting losses from the drop in the long position's value.Moving against ArriVent Stock
| 0.71 | MTEM | Molecular Templates | PairCorr |
| 0.67 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.62 | TPST | Tempest Therapeutics | PairCorr |
| 0.6 | ME | 23Andme Holding | PairCorr |
| 0.57 | AGL | agilon health | PairCorr |
The ability to find closely correlated positions to ArriVent BioPharma, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ArriVent BioPharma, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ArriVent BioPharma, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ArriVent BioPharma, Common to buy it.
The correlation of ArriVent BioPharma, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ArriVent BioPharma, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ArriVent BioPharma, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ArriVent BioPharma, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for ArriVent Stock Analysis
When running ArriVent BioPharma,'s price analysis, check to measure ArriVent BioPharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ArriVent BioPharma, is operating at the current time. Most of ArriVent BioPharma,'s value examination focuses on studying past and present price action to predict the probability of ArriVent BioPharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ArriVent BioPharma,'s price. Additionally, you may evaluate how the addition of ArriVent BioPharma, to your portfolios can decrease your overall portfolio volatility.